Objectives: We sought to examine the impact of direct-to-consumer advertising (DTCA) and pharmaceutical promotion to physicians on the likelihood that (1) an individual diagnosed with depression received antidepressant medication and that (2) antidepressant medication was used for the appropriate duration. Research Design and Subjects: A quasiexperimental design was used to examine treatment patterns of 30,621 depressed individuals whose insurance claims were included in the MarketScan database from 1997 through 2000. The main explanatory variables were spending on DTCA, detailing to physicians, and free samples for 6 antidepressant medications. Results: Individuals diagnosed with depression during periods when class-level antidepressant DTCA spending was highest (cumulative spending more than $18.5 million) had 32% higher relative odds of initiating medication therapy compared with those diagnosed during periods when DTCA spending was lowest (P Ͻ 0.0001). Free samples of medications dispensed to physicians had no effect on odds of initiating antidepressant use. Class-level DTCA spending on antidepressants had a small positive effect on the duration of antidepressant use, whereas DTCA spending for the specific medication taken by an individual had no effect on treatment duration. Detailing spending at the class or product level had no significant effect on duration of treatment with an antidepressant medication. Conclusions: Our results suggest that DTCA of antidepressants was associated with an increase in the number of people diagnosed with depression who initiated medication therapy. DTCA was associated with a small increase in the number of individuals treated with antidepressants who received the appropriate duration of therapy.
D
epression is a highly prevalent condition that results in substantial functional impairment.
1,2 A wide range of effective pharmacologic and psychosocial treatments is available for individuals with depression. [3] [4] [5] [6] Yet, according to recent epidemiologic studies, roughly half of individuals with depression receive no treatment. 7 Moreover, those who receive care for depression frequently fail to receive the proper duration of treatment despite its importance for lowering the risk of relapse. [7] [8] [9] [10] [11] [12] National treatment guidelines have been developed to improve the quality of care provided to people with depression. In addition, there are numerous initiatives to improve access to depression treatment through public education and screening programs and local efforts to improve the quality of depression treatment in primary care settings. [13] [14] [15] [16] [17] The pharmaceutical industry has a substantial economic interest in the way medications are used for treatment of depression. Newer antidepressant medications have been heavily promoted to physicians through detailing (visits from pharmaceutical sales representatives to physicians), the provision of free samples, educational meetings and events, and advertising in professional journals. Studies of drug marketing suggest that promotion to physicians is effective in influencing drug choice. 18 -20 In recent years, pharmaceutical manufacturers have also marketed antidepressant medications directly to consumers through the mass media. Direct-to-consumer advertising (DTCA) has been criticized for leading to inappropriate use of medications and for unnecessarily driving up drug spending. 21, 22 Proponents of DTCA argue that it increases awareness and expands the treatment of underdiagnosed conditions, such as hypercholesterolemia and depression. 23, 24 A recent study of DTCA found that advertising by individual products increased total sales in the associated therapeutic classes. 25 A study of cholesterol-lowering medications found that DTCA had a small-but-positive impact on adherence to medication therapy. 18 Consumer surveys have shown that DTCA motivates people to discuss previously untreated conditions with their physician. [27] [28] [29] [30] Moreover, surveys suggest that a substantial number of people receive prescriptions as a result of seeing an ad for a medication but that the effects of DTCA on patient adherence to medication therapy are unclear. [27] [28] [29] [30] Unfortunately, data from surveys are of limited value in gauging the effects of advertising on rates of treatment initiation and continuation because there is no apt "control group" of patients who have not been exposed to DTCA.
We are aware of no previous studies that assessed the impact of DTCA or physician promotion on the quality of care for depression. In this study, we examined the impact of consumer-and physician-directed marketing of antidepressants on (1) the likelihood that someone diagnosed with a new episode of depression received antidepressant medication and (2) whether they received antidepressant medication for the appropriate duration.
METHODS

Overview
The level of spending on promoting antidepressant medications to consumers and physicians has varied by product over time and for the antidepressant class as a whole. This study assessed the association between variation in aggregate monthly spending on pharmaceutical promotion for antidepressants and patterns in the treatment of depression between January 1997 and December 2000.
Data
The dataset used in the analysis consisted of health insurance claims for use of medical services and prescription drugs and marketing data on pharmaceutical promotion. We focused on 6 antidepressants approved by the Food and Drug Administration for the treatment of depression. These medications, which target serotonin, belong to 3 categories of antidepressants called selective serotonin reuptake inhibitors (fluoxetine, sertraline, paroxetine, and citalopram), serotonin norepinephrine reuptake inhibitors (venlafaxine), and serotonin antagonist and reuptake inhibitors (nefazodone). None of the drugs' patents had expired before the end of the study period. Older-generation antidepressants, such as tricyclic antidepressants, were not included because none were marketed directly to consumers.
The medical claims data were obtained from the MarketScan database (The Medstat Group, Ann Arbor, MI). MarketScan contains medical and pharmacy claims for beneficiaries of a group of large self-insured companies. The data set for 1997 through 2000 contain enrollment information and claims records for individuals from 30 large employers located around the United States. The data set also includes information on the benefit designs of the indemnity and managed care plans used by these employers.
We used drug-specific and class-level monthly data on 3 forms of pharmaceutical promotion: DTCA (including print, radio, and television advertising), detailing to physicians, and free samples of drugs left with physicians. We obtained monthly data on DTCA spending from Competitive Media Reporting, which tracks local and national advertising campaigns. Data on monthly spending on detailing to physicians were obtained from Scott-Levin, Inc., an independent medical information company that conducts market research on the pharmaceutical industry. Scott-Levin imputes spending on detailing from a panel of more than 11,000 officebased and hospital-based physicians who track their encounters with pharmaceutical representatives. The panel is geographically representative, includes members of 31 clinical specialties, and accounts for roughly 2% of the US physician population. Monthly data on the units of free samples dispensed to office-based physicians were obtained from IMS Health, another medical information company. IMS Health uses a panel of more than 1200 medical practice staff members who monitor the quantity of the prescription drugs provided by sales representatives in the form of samples.
Study Sample
The unit of analysis for this study was an episode of treatment of depression. We constructed episodes based on the outpatient and prescription drug claims for patients between the ages of 18 and 64. Those patients younger than 18 years of age were eliminated because the depression guidelines used for this study were not applicable to that age group. Patients aged 65 and older were eliminated because outpatient claims data were likely incomplete for Medicare-eligible enrollees.
The index event for an episode of depression was an outpatient visit for one of the following Diagnostic and Statistical Manual Version IV (DSM-IV) diagnoses: major depression current episode (ICD-9 code 296.2x); major depression recurrent episode (ICD-9 code 296.3x); depression not elsewhere classified (ICD-9 code 311x); or dysthymia, anxiety depression, or prolonged depressive reaction (ICD-9 code 300.4x).
Requiring episodes to originate with an outpatient visit for depression minimizes the chance of including subjects who are using one of the study medications for a condition other than depression. 31, 32 An episode was considered terminated when an individual did not have an outpatient visit for depression or a prescription drug claim for one of the study medications for 2 months.
Subjects had to meet a number of additional inclusion criteria. We required patients to be enrolled in a MarketScan health plan for at least 6 months before the start of an episode and at least 6 months after the episode start date to prevent censoring of observations. To ensure correct identification of an episode's start date, a 6-month pretreatment period was imposed during which there could be no indication of diagnosis or treatment of depression. Hence, all episodes began between July 1, 1997, and June 30, 2000. In addition, we required episodes to include a second confirmatory diagnosis of depression for inclusion in the study. We excluded individuals with diagnoses of bipolar disorder or schizophrenia because their treatment is likely to be significantly affected by these comorbidities. We also excluded individuals enrolled in health plans that did not offer prescription drug coverage.
Outcome Measures
We examined 2 outcomes: (1) whether an episode of depression involved the initiation of antidepressant use with one of the study medications within 60 days of the episode start date and (2) if treated with one of the study antidepressants, whether the depressed patient received an appropriate duration of medication treatment consistent with national depression treatment guidelines.
The guidelines for the treatment of major depression state that if medication treatment is chosen, it should be provided until symptoms are alleviated (usually in 10 -12 weeks) and then continued for an additional period of 4 to 9 months to prevent relapse. 4 -5 To be conservative, our measure of the appropriate duration of therapy was whether the patient filled prescriptions for at least 4 months of treatment with the study drugs within the first 6 months of an episode.
Analysis
We used logistic regression analyses to estimate the impact of promotion on the initiation and duration of medication treatment of depression. In the analysis of whether medication treatment was initiated, the main explanatory variables used were spending on DTCA and units of free samples dispensed to physicians. Total therapeutic class-level spending for both types of promotion was used because initiation of medication therapy could have resulted from promotional spending of any drug in the class. Detailing spending and units of free samples were highly correlated (Spearman correlation coefficient ϭ 0.70). Including both variables in the analysis would have created multicollinearity problems thereby making it infeasible to separate the individual effects of the 2 factors.
Previous studies of drug marketing have found that although the effects of advertising last beyond the period during which marketing expenditures are incurred, these effects diminish over the course of time. 33 Thus, we constructed cumulative measures of spending on advertising to consumers and physician promotion and treated both forms of promotion as depreciating assets. We used promotional spending from the month in which the episode started plus the discounted sum of spending from the previous 6 months. We applied monthly depreciation rates of 0.3% for detailing and 11% for DTCA based on estimates from previous analyses of pharmaceutical promotion. 33 We divided promotional spending into quartiles and calculated odds ratios (ORs) using the lowest quartile as the reference group. Analyses using continuous measures of promotional spending yielded qualitatively similar results but required a restrictive linear form for the promotional effect.
The covariates included were patient age, sex, geographic region, employment status (employed vs. an employee's spouse or dependent, or a retiree), whether the diagnosis coded was major depression (as opposed to dysthymia or other depression), whether the episode was the first in our data collection period, provider specialty (psychiatrist; other physician ͓primarily primary care providers͔; or a therapist, psychologist, or mental health clinic), whether the individual's health plan used capitated payments to reimburse providers, the mean copayment for antidepressant medications in the patient's insurance plan, and the patient's coinsurance rate for outpatient psychiatric services. Given that our analytical strategy relied on temporal variation in promotional spending and treatment patterns, we included linear and quadratic monthly time trends in the analyses to adjust for secular trends in the treatment of depression. We also used an indicator variable for episodes that began in January because a disproportionate share of episodes (14% of total) started in that month.
In the duration of treatment analysis, the main explanatory variables were spending on DTCA and spending on detailing to physicians. Because patients had initiated treatment with a particular brand of antidepressant, we assessed the extent to which their likelihood of receiving the appropriate duration of treatment was associated with promotional spending for the brand they were prescribed as well as that for other drugs in the class. Thus, we included 4 promotional variables in the analysis of treatment duration: spending on detailing for the drug taken (own product detailing), spending on detailing for the other drugs in the class (others' detailing), spending on DTCA for the drug taken (own product DTCA), and spending on DTCA for the other drugs in the class (others' DTCA). We used cumulative promotional expenditures (spending in the month in which the episode started, plus the discounted sum of the previous 6 months' spending).
The same covariates from the analysis of whether drug treatment was initiated were used in the model of treatment duration with 4 exceptions. Because all of the individuals who were included in the treatment duration analysis filled prescriptions for antidepressants, we used actual prescription drug copayment rather than mean copayment by health plan.
We included 3 additional variables: the brand of antidepressant the patient was initially prescribed, whether a medication switch occurred during the first 6 months of the episode, and whether the individual had at least 2 sessions of concomitant psychotherapy.
Because we used data from a large insured population over time, there were potential clustering effects from repeatedly observing the same individuals. To address this problem for both analyses, we used the General Estimating Equations estimator of Liang and Zeger to obtain consistent estimates of standard errors given the non-Gaussian nature of our outcome variables. 34 All analyses were performed using SAS statistical software, version 8.2 (SAS Institute, Cary, NC).
RESULTS
The MarketScan database contained the medical claims for 5,718,683 individuals between 1997 and 2000. We identified our study population from the 62% of individuals in firms that provided the Medstat Group with complete data on medical and pharmacy claims, and insurance benefit design. A total of 30,621 individuals with 36,062 episodes of depression met our study criteria and were included in the analysis of medication treatment initiation. We estimated the impact of drug promotion on the duration of treatment using the subsample of episodes in which medication treatment was initiated (10,490 individuals with 11,306 episodes). Table 1 provides the characteristics of the total sample used in the analysis of treatment initiation and the subsample used in the analysis of treatment duration.
We found that 31% (n ϭ 11,306) of the depressive episodes resulted in a prescription drug claim for an antidepressant within 60 days of the episode start date. Of those receiving medication for depression, 60% (n ϭ 6753) filled at least 4 prescriptions for an antidepressant in the first 6 months of an episode. Figures 1 and 2 show the product-level spending on DTCA and detailing for antidepressants between 1997 and 2000. There was significant variation in spending on both forms of promotion. Two of the drugs (sertraline and citalopram) had zero spending on DTCA during the entire study period. Fluoxetine and paroxetine had the highest levels of spending on DTCA. All of the study drugs had positive expenditures on physician detailing, although there was substantial variation in the levels of spending.
Spending on DTCA and Detailing
Initiation of Drug Treatment
After controlling for secular trends in the treatment of depression and other factors, we estimated a small positive effect of DTCA spending on the probability that a person received drug treatment given a diagnosis of depression (Table 2 ). Individuals diagnosed with depression during periods when class-level antidepressant DTCA spending was in the top quartile (cumulative spending of more than $18.5 million) had 32% higher relative odds of initiating medication therapy compared with those diagnosed during periods when DTCA spending was in the bottom quartile (95% confidence interval ͓CI͔1.18 -1.48; P Ͻ 0.0001).
Providing free samples of antidepressant medication to physicians did not appear to significantly increase rates of treatment with antidepressants. We found that individuals who initiated treatment after periods when cumulative free sample spending was in the top quartile (more than 103.9 million units) were no more likely to initiate medication therapy than individuals who were diagnosed during periods of low free sample spending (OR 1.07; 95% CI 0.90 -1.27; P ϭ 0.45).
Individuals in our sample appeared to be sensitive to the out-of-pocket cost of drugs and other forms of treatment of depression. Individuals facing a copay of more than $15.00 for an antidepressant were much less likely to initiate medication therapy than those facing a copay of $5.00 or less (OR 0.70; 95% CI 0.60 -0.81; P Ͻ 0.0001). Individuals enrolled in health plans that paid a higher share of outpatient psychiatric services were less likely to initiate treatment with an antidepressant.
Individuals who were treated primarily by physicians, enrolled in capitated health plans, and treated for major depression were more likely to initiate treatment with an antidepressant during an episode of depression. Women, residents of southern states, and employees (as opposed to retirees or dependents) were also more likely to initiate medication therapy. Older individuals (results not shown) and those seeking care for a second or third episode of depression during our data collection period were less likely to initiate medication therapy for depression.
Appropriate Duration of Treatment
The likelihood that an individual taking antidepressant medication received at least 4 months of treatment was not significantly different across DTCA spending levels for the specific brand of medication taken by the individual (Table  3) . When the promotional spending of other antidepressants was taken into account, DTCA had a small positive effect on the duration of treatment once it reached a certain threshold (top quartile spending of $21.8 million or more; OR 1.30; 95% CI 1.06 -1.62; P Ͻ 0.05).
Neither the detailing spending for the drug taken nor the detailing spending for the other drugs in the class had any significant effect on the duration of treatment with an antidepressant medication.
Treatment duration did not necessarily decrease with higher cost sharing for prescription drugs. Individuals who faced copays of $15.00 or more were no more likely to receive the proper duration of care than those facing copays of less than $5.00. Women, individuals who were older (results not shown), switched medications, were treated primarily by a physician, enrolled in a capitated health plan, and initiated treatment with fluoxetine were more likely to fill at least 4 prescriptions for an antidepressant. Residents of southern states were less likely to receive the proper duration of medication treatment. Individuals being treated for a repeat episode or who had 
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concomitant use of psychotherapy were no more likely to receive the proper duration of antidepressant treatment (results not shown).
DISCUSSION
One of the chief arguments in support of DTCA of prescription drugs is that it increases the number of individuals who seek care for chronic and disabling conditions such as depression. Our results suggest that periods of high DTCA spending are followed by an increase in the number of individuals diagnosed with depression who initiate medication therapy.
DTCA for antidepressants may increase the number of individuals receiving medication treatment of depression by promoting awareness of the symptoms of depression and the therapies available. Advertising for antidepressants may aid patients in identifying symptoms of depression and activate them to discuss their symptoms with their treatment provider. For conditions like depression, which are associated with social stigma, advertising may reduce negative views associated with treatment. Advertising also may affect treatment choice for those already receiving care for depression. For example, an individual who had received psychotherapy for a previous episode of depression may, upon seeing an antidepressant advertisement, request medication treatment in combination with or in lieu of behavioral treatment. Because our analyses of DTCA were conditional on diagnosis, we were not able to differentiate between these 2 effects.
Increased provision of free samples of antidepressants by pharmaceutical companies did not result in an increase in the number of individuals with depression who initiated drug treatment. Other studies have found that although detailing has little influence on the total number of individuals receiving treatment, it has a substantial effect on medication choice. Similarly, free samples may have a larger impact on medication selection than on the decision to initiate medication treatment. Our analyses were not directed at this issue.
Patients' receipt of treatment of depression for an adequate duration of time may reflect both their willingness to continue with pharmacotherapy and physicians' clinical management. DTCA has been promoted as a useful tool for communication and improving adherence to medication therapy. 23 We found no association between brand-level spending on DTCA and the likelihood that an individual received the appropriate duration of treatment. When the promotional spending of other drugs in the class was taken into account, however, we found that consumer promotion had a small positive impact on treatment duration but only at the highest level of spending.
Nonadherence to prescribed medication therapy is a complex problem resulting from medical, social, behavioral, and economic factors. Multifaceted interventions that involve one-on-one patient follow-up and individualized education have been more successful in prolonging the course of antidepressant therapy than programs involving the distribution of informational leaflets on the use of antidepressants. 35, 36 Pharmaceutical firms have an economic interest in maintaining patients on medication for chronic conditions like depression. Recognizing the high rates of discontinuation of medication therapy among individuals with chronic illnesses, some pharmaceutical firms have tailored their DTCA campaigns toward improving adherence. 37, 38 Mass media advertising campaigns may, however, be better suited for bringing patients into treatment than for increasing rates of adherence. Some manufacturers have developed programs that allow patients taking a particular medication to access information, join support groups, and sign up for electronic reminders to refill prescriptions. The effectiveness of these programs at improving adherence has not been evaluated in the medical literature.
The duration of treatment is also driven by physiciandetermined factors, such as the initial medication choice and the care management provided by the physician. The bulk of antidepressant promotional spending has been aimed at physician detailing (Figs. 1 and 2) . The one-on-one nature of detailing may lend itself well to education on the proper duration of antidepressant use. Indeed, experiments have shown "academic detailing" to be highly effective in chang- DTCA and Adherence to Depression Treatment ing prescribing behavior. 39, 40 We found no evidence, however, that detailing affected rates of adherence to guideline treatment of depression (Table 3) . Studies of the content of detailing visits to physicians suggest that the focus of these interactions is on highlighting the comparative advantages of one drug within a class over another. 41, 42 This study has several limitations. There may be unobserved factors driving the association between DTCA and initiation of medication treatment of depression. We used aggregate data on promotional spending and did not observe an individual's level of exposure to advertising or the frequency of contact between pharmaceutical sales representatives and the physicians in our sample. However, given that the price pharmaceutical firms are charged for advertising is correlated with the number of individuals reached, aggregate spending data should provide a valid measure of exposure. The MarketScan claims represent the health care experience of employees (or their dependents) who work primarily for Fortune 200 companies that offer relatively generous health insurance benefits and may thus not be representative. Other populations, such as the elderly, the uninsured, or those with less generous coverage, may have a differential response to pharmaceutical advertising. We were not able to capture information on antidepressant prescriptions paid out-ofpocket or through dual coverage, although we see no reason why this should bias our findings on promotion.
Our analyses of treatment duration evaluated the effects of brand-specific DTCA spending. This gross measure lumps together the impact of DTCA for a diverse group of medications and may obscure evidence of an impact for individual drugs where the marketing strategies have emphasized quality and length of treatment. Paroxetine's DTCA campaigns focused largely on that product's therapeutic indications for treating anxiety disorders. Our analyses, which were based on individuals diagnosed with depression, may underestimate the effect of DTCA for paroxetine. We used claims data and may underidentify patients with depression by excluding those who have an outpatient visit in which a depression diagnosis is not recorded either because of stigma or for other reasons. [43] [44] [45] Claims data also lack information on the severity of illness and potentially important sociodemographic predictors such as education. Finally, the effects of drug marketing are likely to vary depending on the ease of patient self-diagnosis, the degree to which conditions are undertreated, and provider specialty. Thus, the findings from this study may not necessarily be generalizeable to other medication classes.
CONCLUSION
This is one of the first studies to examine the impact of DTCA and physician promotion on quality of care. Our results suggest that advertising antidepressants to consumers may increase the likelihood that an individual with depression initiates medication therapy. Free samples of antidepressants, on the other hand, had no effect on medication use. We found no evidence, however, that pharmaceutical promotion to consumers or physicians has an important impact on the likelihood that therapy would be continued in a way that meets existing guidelines. To the extent that DTCA increases demand for medications, it is important to understand whether the expanded use represents appropriate prescribing. This important issue deserves further investigation.
